{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:45:57Z","timestamp":1782906357316,"version":"3.54.5"},"reference-count":19,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T00:00:00Z","timestamp":1517270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Pfizer Inc","award":["NCT01564784"],"award-info":[{"award-number":["NCT01564784"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2018,4,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Inotuzumab ozogamicin (InO) has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed\/refractory acute lymphoblastic leukemia (ALL) in the INO\u2010VATE trial. This subset analysis compared the efficacy and safety of InO in younger and older patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Intent\u2010to\u2010treat analyses of morphologic responses and overall survival (OS) included 326 randomized patients, and safety assessments included 307 patients receiving 1 or more doses of the study treatment. Of the 326 patients, 164 received InO at a starting dose of 1.8\u2009mg\/m<jats:sup>2<\/jats:sup>\/cycle (0.8\u2009mg\/m<jats:sup>2<\/jats:sup> on day 1 and 0.5\u2009mg\/m<jats:sup>2<\/jats:sup> on days 8 and 15 of a 21\u2010 to 28\u2010day cycle [\u22646 cycles]); 60 patients were aged \u226555 years, and 104 were aged &lt;55 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>For older and younger patients, the median duration of InO therapy and the types and frequencies of adverse events of any grade were generally similar. Although the remission rates, median duration of remission (DOR), and progression\u2010free survival were similar with InO for those aged &lt;55 years and those aged \u226555 years, OS was longer for younger patients (median, 8.6 vs 5.6 months; hazard ratio, 0.610). Among patients proceeding to hematopoietic stem cell transplantation after InO treatment (28% of older patients and 58% of younger patients), the incidence of veno\u2010occlusive disease was greater in older patients (41% vs 17%). The study database was not locked at the time of this analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>InO was tolerable in older patients with relapsed\/refractory ALL. Although OS was longer for younger patients versus older patients, InO demonstrated high response rates with similar DOR in the 2 age groups. <jats:bold><jats:italic>Cancer<\/jats:italic> 2018;124:1722\u201032<\/jats:bold>. \u00a9 <jats:italic>2018 American Cancer Society<\/jats:italic><\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.31249","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T13:15:23Z","timestamp":1517318123000},"page":"1722-1732","source":"Crossref","is-referenced-by-count":53,"title":["Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO\u2010VATE"],"prefix":"10.1002","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias J.","family":"Jabbour","sequence":"first","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology\/Hematologic Malignancies Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University of M\u00fcnster M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology University of Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Divisions of Hematology and Oncology Stanford Cancer Institute Stanford California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[{"name":"Department of Medicine Goethe University Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3386-6540","authenticated-orcid":false,"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology University of California Irvine Orange California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer, Inc Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Luisa","family":"Paccagnella","sequence":"additional","affiliation":[{"name":"Pfizer, Inc Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sleight","sequence":"additional","affiliation":[{"name":"Pfizer, Inc Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Vandendries","sequence":"additional","affiliation":[{"name":"Pfizer Inc Cambridge Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali S.","family":"Advani","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology\/Hematologic Malignancies Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29383"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-379016"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23819"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703382"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.679359"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70386-2"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28136"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_2_8_12_1","first-page":"266","article-title":"Treatment of acute lymphoblastic leukemia in older adults: now and the future","volume":"15","author":"Yilmaz M","year":"2017","journal-title":"Clin Adv Hematol Oncol."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30103-5"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.6193"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1382"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.140"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-264077"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-266551"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood.V126.23.83.83","article-title":"Frontline inotuzumab ozogamicin in combination with low\u2010intensity chemotherapy (mini\u2010hyper\u2010CVD) for older patients with acute lymphoblastic leukemia (ALL) [abstract]","volume":"125","author":"Jabbour E","year":"2015","journal-title":"Blood."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.31249","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:25:47Z","timestamp":1760286347000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,4,15]]}},"alternative-id":["10.1002\/cncr.31249"],"URL":"https:\/\/doi.org\/10.1002\/cncr.31249","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]}}}